Keywords: Qiagen, Cellestis, Diagnostics, M&A
Australian diagnostics firm Cellestis gets $355 million offer from Qiagen
Article | 05 April 2011
In another recent move on an Australian medical company, Netherlands-based Qiagen (Nasdaq: QGEN) has reached an agreement to acquire Cellestis ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
